Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Feb;106(2):375-9.
doi: 10.1016/S0161-6420(99)90079-9.

Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial

Affiliations
Clinical Trial

Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial

B Rahmani et al. Ophthalmology. 1999 Feb.

Abstract

Objective: Oral antifibrinolytics, oral steroids, and no oral treatment are the preferred medical treatments for traumatic hyphema. Antifibrinolytics and steroids have decreased the chance of rebleeding in some studies but failed to alter the clinical course in others. Rate of secondary hemorrhage seems variable among different geographic and ethnic groups of patients. Comparison of the treatments in each population is necessary to document the most effective method of preventing recurrent hemorrhage.

Design: Randomized, placebo-controlled, clinical trial.

Participants: Two hundred thirty-eight patients in whom hyphema developed after a blunt trauma entered the study.

Intervention: Eighty patients received 75 mg/kg per day oral tranexamic acid (TA) divided into 3 doses, 80 patients received a placebo with the same number of tablets and frequency as those of the TA group, and 78 patients received 0.75 mg/kg per day oral prednisolone divided into 2 doses.

Main outcome measure: Secondary hemorrhage during the hospital course was measured.

Results: Secondary hemorrhage occurred in 8 patients (10%) of the TA group, 14 patients (18%) of the prednisolone group, and 21 patients (26%) of the placebo group. The difference between the incidence of rebleeding between TA and placebo groups was statistically significant (P = 0.008). Patients receiving a placebo had a greater chance of secondary bleeding than did patients receiving TA (odds ratios = 3.2; 95% confidence interval = 1.3, 7.5). The incidences of rebleeding were not significantly different in placebo versus prednisolone groups (P = 0.21) and TA versus prednisolone groups (P = 0.15).

Conclusion: In a population with a high rate of secondary bleeding, TA is more effective than oral prednisolone or no oral treatment in preventing rebleeding among patients with traumatic hyphema.

PubMed Disclaimer

Comment in

Similar articles

Cited by

MeSH terms

LinkOut - more resources